aspirin has been researched along with Hematologic Malignancies in 4 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among previous studies examining the associations of over-the-counter analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) and incident hematologic malignancies, results were inconsistent for NSAIDs but suggested an increased risk with acetaminophen (paracetamol)." | 7.77 | Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. ( Brasky, TM; Milano, F; Walter, RB; White, E, 2011) |
| "Among previous studies examining the associations of over-the-counter analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) and incident hematologic malignancies, results were inconsistent for NSAIDs but suggested an increased risk with acetaminophen (paracetamol)." | 3.77 | Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. ( Brasky, TM; Milano, F; Walter, RB; White, E, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robier, C | 1 |
| Stettin, M | 1 |
| Neubauer, M | 1 |
| Keohane, C | 1 |
| McLornan, DP | 1 |
| Sanchez, K | 1 |
| Connor, C | 1 |
| Radia, D | 1 |
| Harrison, CN | 1 |
| Robak, P | 1 |
| Smolewski, P | 1 |
| Robak, T | 1 |
| Walter, RB | 1 |
| Milano, F | 1 |
| Brasky, TM | 1 |
| White, E | 1 |
1 review available for aspirin and Hematologic Malignancies
| Article | Year |
|---|---|
The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Etodolac; Hematologic Neoplasms; He | 2008 |
1 trial available for aspirin and Hematologic Malignancies
| Article | Year |
|---|---|
The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms.
Topics: Aspirin; Biomarkers; Female; Hematologic Neoplasms; Humans; Janus Kinase 2; Male; Middle Aged; Nitri | 2015 |
2 other studies available for aspirin and Hematologic Malignancies
| Article | Year |
|---|---|
Changes in response to antiaggregatory treatment in patients with myeloproliferative neoplasms: a sequential study using multiple electrode aggregometry.
Topics: Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Case-Control Studies | 2013 |
Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coh | 2011 |